Novartis’ $2B Takeover of Endocyte, Revolution-Warp Drive, & Amgen’s Foray in DNA Sequencing

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.